Tuesday | Business Wire
Broadpoint.Gleacher Expands Industrials Investment Banking
Broadpoint Capital, Inc., a broker-dealer subsidiary of Broadpoint Gleacher Securities Group, Inc.
Customer Interaction Solutions
www.PicksThatMove.com: "Picks that move" Alerts, December 16, 2009: FACT, LSBX, AMAC, JBLU and ARTG
December 16, 2009 DFacet Biotech Corporation trading at $16.07 on a volume of 742,804 shares In a press release on December 16, Facet Biotech Enters Agreement With The Baupost Group to Allow Purchase of Additional Shares REDWOOD CITY, CA, Dec 16, 2009 Facet Biotech Corporation today announced that in response to a request from The Baupost Group, ...
Facet shares slide on stock update
As of Dec. 16, Baupost held a 14% position in Facet. Under a new amendment to Facet's Rights Agreement, Baupost will be able to own up to 20% of Facet's float.
Public relations, press release distribution, investor relations, SEC filing
The study... NORTH AUGUSTA, S.C.-- --The Lightstone Group announced today that Sonic Drive-In has signed a 40,000-square-foot, long-term lease at its Martintown Plaza shopping center in North Augusta... NEW YORK-- --Certain BlackRock closed-end funds announced distributions today as detailed below.
News and FDA Updates for Neoprobe
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.
Facet Biotech And Bristol-Myers Squibb Report Promising Phase I/II...
Main Category: Melanoma / Skin Cancer Also Included In: Pharma Industry / Biotech Industry Clinical Trials / Drug Trials Facet Biotech Corporation and Bristol-Myers Squibb Company announced that potentially promising data from a Phase I/II study of elotuzumab, an investigational humanized antibody being studied for the treatment of relapsed ...
Facet rejects Biogen takeover bid as too low
Biogen has offered to pay $17.50 a share in cash for Facet, upped from its previous bid of $14.50 a share.
Facet to respond soon to raised Biogen offer
Three months of volleying over a takeover bid by Biogen Idec Inc. will come to a head next week, when Facet Biotech Corp.
Trubion And Facet Biotech Announce Presentation Of Positive TRU-016...
Main Category: Lymphoma / Leukemia / Myeloma Also Included In: Pharma Industry / Biotech Industry Clinical Trials / Drug Trials Trubion Pharmaceuticals, Inc.
Facet Biotech and Bristol-Myers Squibb Report Promising Phase I/II...
Clinical activity seen for elotuzumab plus lenalidomide and low dose dexamethasone Results support initiation of global Phase II study REDWOOD CITY, Calif.
Our Final Offer (Maybe)! That's a FACT
There are two rules in negotiations. Don't be the first to name a number and don't get in a bidding war with yourself.
News and FDA Updates for AdvanSource
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.
Shares of the following companies may have unusual moves in U.S. trading. Stock symbols are in parentheses, and prices are as of 9 a.m. in New York.
Biogen Idec Inc. today announced that it has increased its offer to purchase all of the outstanding shares of Facet Biotech Corporation to $17.50 per share in cash, representing an increase of $3.00 per share, or 21%, over its previous offer.
First Albany Companies, Inc.: Warming Up or Cooling Off?
Together, we are all trying to build our fortune by finding well-run companies at bargain-basement prices.
Facet Biotech Reports Third Quarter 2009 Financial Results
"We are executing on our development programs while remaining vigilant on cost containment and expense management," said Faheem Hasnain, president and chief executive officer of Facet Biotech.
Movers & Shakers: Monday's biggest gaining and declining stocks
Among the companies whose shares are expected to see active trade in Monday's session are Allion, Apple, Eaton, Facet Biotech, Hasbro, InterDigital, Nokia, Pfizer, TI and Weatherford.
Large Cap Biotech Earnings Preview
Biotech has traditionally been a sector that has fared better than most during economic downturns.
Biogen Should Bid Near $25 Per Facet Share
Facet Biotech By Merriman Curhan Ford WE WHOLEHEARTEDLY agree with Facet Biotech management that the offer from Biogen Idec is inadequate and not in the best interest of shareholders.
Frank Castelluccio Joins Broadpoint.Gleacher as Executive Managing Director and Head of Operations
Broadpoint Capital, Inc., a broker-dealer subsidiary of Broadpoint Gleacher Securities Group, Inc.
Also on Topix